Editas Medicine Ownership
| EDIT Stock | USD 5.55 0.06 1.07% |
Shares in Circulation | First Issued 2014-12-31 | Previous Quarter 81.6 M | Current Value 81.7 M | Avarage Shares Outstanding 49.9 M | Quarterly Volatility 19.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Editas |
Editas Stock Ownership Analysis
About 80.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.46. Some equities with similar Price to Book (P/B) outperform the market in the long run. Editas Medicine recorded a loss per share of 2.02. The entity had not issued any dividends in recent years. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 264 people. To learn more about Editas Medicine call Gilmore MD at 617 401 9000 or check out https://www.editasmedicine.com.Besides selling stocks to institutional investors, Editas Medicine also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Editas Medicine's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Editas Medicine's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Editas Medicine Quarterly Liabilities And Stockholders Equity |
|
Editas Medicine Insider Trades History
Less than 1% of Editas Medicine are currently held by insiders. Unlike Editas Medicine's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Editas Medicine's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Editas Medicine's insider trades
Editas Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Editas Medicine is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Editas Medicine backward and forwards among themselves. Editas Medicine's institutional investor refers to the entity that pools money to purchase Editas Medicine's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Millennium Management Llc | 2023-09-30 | 1.2 M | Credit Suisse First Boston (csfb) | 1.1 M | Two Sigma Advisers, Llc | 2023-09-30 | 1.1 M | Jpmorgan Chase & Co | 2023-09-30 | 1.1 M | Nuveen Asset Management, Llc | 2023-09-30 | 949.1 K | Northern Trust Corp | 2023-09-30 | 888.7 K | Charles Schwab Investment Management Inc | 2023-09-30 | 689 K | D. E. Shaw & Co Lp | 2023-09-30 | 668.7 K | Man Group Plc | 2023-09-30 | 638.2 K | Vanguard Group Inc | 2023-09-30 | 8.5 M | Blackrock Inc | 2023-09-30 | 8.2 M |
Editas Medicine Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Editas Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Editas Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Editas Medicine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
O'neill Gilmore Neil over two weeks ago Disposition of 6486 shares by Oneill Gilmore Neil of Editas Medicine at 9.5032 subject to Rule 16b-3 | ||
Michelle Robertson over six months ago Sale by Michelle Robertson of 1527 shares of Editas Medicine | ||
Michelle Robertson over six months ago Sale by Michelle Robertson of 949 shares of Editas Medicine | ||
Michelle Robertson over a year ago Acquisition by Michelle Robertson of 31500 shares of Editas Medicine subject to Rule 16b-3 |
Editas Medicine Corporate Filings
| 16th of April 2024 Other Reports | ViewVerify | |
13A | 10th of April 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 5th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 28th of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Pair Trading with Editas Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Editas Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will appreciate offsetting losses from the drop in the long position's value.Moving together with Editas Stock
| 0.76 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against Editas Stock
| 0.61 | MRKR | Marker Therapeutics | PairCorr |
The ability to find closely correlated positions to Editas Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Editas Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Editas Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Editas Medicine to buy it.
The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Editas Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Editas Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Editas Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Editas Stock analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 1.028 | Quarterly Revenue Growth 8.187 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.